Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer
Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer
复制标题
DOI：
10.1088/0031-9155/52/13/l01
复制
发表时间：
2007-07-07
影响因子：
3.5
通讯作者：
Graham, Peter
中科院分区：
文献类型：
--
作者：
Allen, Barry J.;Raja, Chand;Graham, Peter
靶向α治疗（达特）是一种新兴的治疗方式，被认为最适合癌症微转移，白血病和淋巴瘤。达特不适用于实体瘤。然而，在一项针对黑色素瘤的全身靶向α治疗的I期临床试验中，几名黑色素瘤患者的皮下和内部肿瘤明显消退。这种反应不能归因于通过靶向α治疗杀死肿瘤中的所有癌细胞。这些新的观察结果支持了最初的假设，即肿瘤可以通过一种称为肿瘤抗血管α治疗的机制来消退。这种效应取决于毛细血管周细胞和邻近癌细胞靶向受体的表达，以及α辐射的短程和高能转移。
Targeted alpha therapy ( TAT) is an emerging therapeutic modality, thought to be best suited to cancer micrometastases, leukaemia and lymphoma. TAT has not been indicated for solid tumours. However, several melanoma patients in a phase 1 clinical trial of systemic targeted alpha therapy for melanoma experienced marked regression of subcutaneous and internal tumours. This response cannot be ascribed to killing of all cancer cells in the tumours by targeted alpha therapy. These new observations support the original hypothesis that tumours can be regressed by a mechanism called tumour anti-vascular alpha therapy. This effect depends on the expression of targeted receptors by capillary pericytes and contiguous cancer cells, and on the short-range and high-energy transfer of alpha radiation.